[Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
- Authors:
- Published online on: September 19, 2022 https://doi.org/10.3892/or.2022.8411
- Article Number: 196
-
Copyright : © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article
Oncol Rep 37: [Related article:] 2215–2226, 2017; DOI: 10.3892/or.2017.5494
Subsequently to the publication of the above article, the authors have realized that a couple of clerical errors were made when writing the article, and wish to correct these errors in a corrigendum statement. First, in the Materials and methods section on p. 2216, the final sentence of the ‘Immunohistochemistry and tissue microarray’ subsection, the authors wish to add a further definition, so that the text reads as follows (changes highlighted in bold): ‘The positive expression of RET was defined as ≥5% staining of a tumor section; high expression was defined as ≥40% staining of a tumor section, and low expression as <40%’. Secondly, in the Results section, ‘Mutation frequency of each gene distributed in 4 biological categories’ subsection, p. 2220, right-hand column, second paragraph, line 17, the sentence written here should have read as follows: ‘The group with the positive expression of RET included 28.9% (26/90) of the patients, and 4 of these patients were defined as high expression’.
The authors are grateful to the Editor of Oncology Reports for allowing them this opportunity to publish a corrigendum, and apologize to the readership of the journal for any inconvenience caused.
